Applied Molecular Transport Inc. (NASDAQ:AMTI) Major Shareholder Epiq Capital Group, Llc Buys 32,380 Shares

Applied Molecular Transport Inc. (NASDAQ:AMTI – Get Rating) major shareholder Epiq Capital Group, Llc purchased 32,380 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $3.88 per share, with a total value of $125,634.40. Following the purchase, the insider now directly owns 8,307,755 shares of the company’s stock, valued at $32,234,089.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

AMTI stock opened at $3.99 on Tuesday. Applied Molecular Transport Inc. has a 1-year low of $3.41 and a 1-year high of $52.71. The business has a fifty day moving average price of $5.78 and a 200-day moving average price of $10.58. The stock has a market capitalization of $154.23 million, a P/E ratio of -1.25 and a beta of 1.93.

Applied Molecular Transport (NASDAQ:AMTI – Get Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.35). Analysts expect that Applied Molecular Transport Inc. will post -3.32 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in Applied Molecular Transport by 6.6% during the first quarter. State Street Corp now owns 456,271 shares of the company’s stock valued at $3,431,000 after acquiring an additional 28,432 shares during the last quarter. Renaissance Technologies LLC increased its position in Applied Molecular Transport by 146.7% during the first quarter. Renaissance Technologies LLC now owns 428,200 shares of the company’s stock valued at $3,220,000 after acquiring an additional 254,600 shares during the last quarter. EPIQ Capital Group LLC increased its position in Applied Molecular Transport by 0.3% during the first quarter. EPIQ Capital Group LLC now owns 9,098,780 shares of the company’s stock valued at $68,423,000 after acquiring an additional 23,292 shares during the last quarter. Ergoteles LLC increased its position in Applied Molecular Transport by 53.0% during the first quarter. Ergoteles LLC now owns 17,404 shares of the company’s stock valued at $131,000 after acquiring an additional 6,031 shares during the last quarter. Finally, BlackRock Inc. increased its position in Applied Molecular Transport by 5.9% during the first quarter. BlackRock Inc. now owns 2,053,572 shares of the company’s stock valued at $15,443,000 after acquiring an additional 114,128 shares during the last quarter. Institutional investors own 71.34% of the company’s stock.

Applied Molecular Transport Company Profile (Get Rating)

Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.

Read More